0000899243-23-005918.txt : 20230222
0000899243-23-005918.hdr.sgml : 20230222
20230222212102
ACCESSION NUMBER: 0000899243-23-005918
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230217
FILED AS OF DATE: 20230222
DATE AS OF CHANGE: 20230222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Glover Bradley
CENTRAL INDEX KEY: 0001867698
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38914
FILM NUMBER: 23655685
MAIL ADDRESS:
STREET 1: C/O CELULARITY INC.
STREET 2: 170 PARK AVENUE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celularity Inc
CENTRAL INDEX KEY: 0001752828
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831702591
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
BUSINESS PHONE: (908) 768-2170
MAIL ADDRESS:
STREET 1: 170 PARK AVE
CITY: FLORHAM PARK
STATE: NJ
ZIP: 07932
FORMER COMPANY:
FORMER CONFORMED NAME: GX Acquisition Corp.
DATE OF NAME CHANGE: 20180912
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-17
0
0001752828
Celularity Inc
CELU
0001867698
Glover Bradley
C/O CELULARITY INC.
170 PARK AVENUE
FLORHAM PARK
NJ
07932
0
1
0
0
See Remarks
Class A Common Stock
2023-02-17
4
A
0
300000
A
354076
D
These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A Common Stock. The RSUs is subject to time-based vesting over a two-year period, with 50% vesting on the one-year anniversary of the grant date, and the remainder vesting on the two-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date.
These shares include 345,310 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting.
Executive Vice President, Chief Operating Officer
/s/ Kyle Fletcher, Attorney-in-Fact
2023-02-22